Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00034983
NCT00034983
Completed
Phase 3

A Worldwide, Multicenter, Double-Blind, Parallel, Active-Controlled, Long-Term Safety Study of MK0869 in Outpatients With Major Depressive Disorder

Merck Sharp & Dohme LLC0 sites900 target enrollmentOctober 29, 2001
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMajor Depressive Disorder
DrugsaprepitantComparator: paroxetine HCL

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Major Depressive Disorder
Sponsor
Merck Sharp & Dohme LLC
Enrollment
900
Primary Endpoint
Long-term safety and tolerability.
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression

Detailed Description

The duration of treatment is 1 year.

Registry
clinicaltrials.gov
Start Date
October 29, 2001
End Date
December 29, 2003
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Long-term safety and tolerability.

Time Frame: Duration of treatment

Secondary Outcomes

  • Sexual dysfunction adverse experiences and gastrointestinal disturbance adverse experiences(Duration of treatment)

Similar Trials

Completed
Phase 3
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)Major Depressive Disorder
NCT00048594Merck Sharp & Dohme LLC800
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)Major Depressive Disorder
NCT00035048Merck Sharp & Dohme LLC540
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)Major Depressive Disorder
NCT00035282Merck Sharp & Dohme LLC450
Unknown
Phase 2
A Study To Evaluate the Safety, Tolerance, Pharmacokinetics/Pharmacodynamics and Efficacy of SYHA1402 Tablets For the Treatment of Patients With Diabetic Peripheral Neuropathy in ChinaDistal Symmetric Polyneuropathy (DSPN)
NCT05116111CSPC ZhongQi Pharmaceutical Technology Co., Ltd.135
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)Major Depressive Disorder
NCT00035295Merck Sharp & Dohme LLC584